Siobhan M Hoscheidt1, Erika J Starks1, Jennifer M Oh1, Henrik Zetterberg2,3, Kaj Blennow2, Rachel A Krause1, Carey E Gleason4,1, Luigi Puglielli1,4, Craig S Atwood4,1, Cynthia M Carlsson4,1,5, Sanjay Asthana4,1,5, Sterling C Johnson4,1,5, Barbara B Bendlin1,5. 1. Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. 2. Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden. 3. Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, UK. 4. Geriatric Research Education and Clinical Center, Wm. S. Middleton Veterans Hospital, Madison, WI, USA. 5. Wisconsin Alzheimer's Institute, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Abstract
BACKGROUND: Type 2 diabetes is associated with an increased risk for Alzheimer's disease (AD). Regulation of normal insulin function may be important in reducing the prevalence of dementia due to AD, particularly in individuals who harbor genetic risk for or have a parental family history of AD. The relationship between insulin resistance (IR) and AD pathology remains poorly understood, particularly in midlife prior to the onset of clinical metabolic disease or cognitive decline. OBJECTIVE: We examined associations between IR as indexed by HOMA-IR, cerebrospinal fluid (CSF) biomarkers of AD pathology, and memory in middle-aged adults enriched for AD. We postulated that higher HOMA-IR and APOEɛ4 carriage would be associated with greater CSF AD pathology and poor memory performance. METHODS: Cognitively asymptomatic middle-aged adults (N = 70, mean age = 57.7 years) from the Wisconsin Alzheimer's Disease Research Center with a parental family history of dementia due to AD underwent lumbar puncture, blood draw, and neuropsychological testing. CSF AD biomarkers including soluble amyloid-β protein precursor β (sAβPPβ), amyloid-β42 (Aβ42), and phosphorylated tau (P-tau181) were examined with respect to HOMA-IR and APOEɛ4 status. Delayed memory performance was examined with respect to HOMA-IR, CSF AD biomarkers, and APOEɛ4 status. RESULTS: Higher HOMA-IR was associated with higher sAβPPβ and Aβ42 . APOEɛ4 carriers had significantly higher levels of sAβPPα, sAβPPβ, and P-tau181/Aβ42 compared to noncarriers. The concurrent presence of higher HOMA-IR and CSF AD pathology predicted worse delayed memory performance. CONCLUSION: Overall, the findings suggest that IR and APOEɛ4 are contributing factors to the development of AD pathology in midlife, and provide support for targeting insulin function as a potentially modifiable risk factor for AD.
BACKGROUND:Type 2 diabetes is associated with an increased risk for Alzheimer's disease (AD). Regulation of normal insulin function may be important in reducing the prevalence of dementia due to AD, particularly in individuals who harbor genetic risk for or have a parental family history of AD. The relationship between insulin resistance (IR) and AD pathology remains poorly understood, particularly in midlife prior to the onset of clinical metabolic disease or cognitive decline. OBJECTIVE: We examined associations between IR as indexed by HOMA-IR, cerebrospinal fluid (CSF) biomarkers of AD pathology, and memory in middle-aged adults enriched for AD. We postulated that higher HOMA-IR and APOEɛ4 carriage would be associated with greater CSF AD pathology and poor memory performance. METHODS: Cognitively asymptomatic middle-aged adults (N = 70, mean age = 57.7 years) from the Wisconsin Alzheimer's Disease Research Center with a parental family history of dementia due to AD underwent lumbar puncture, blood draw, and neuropsychological testing. CSF AD biomarkers including soluble amyloid-β protein precursor β (sAβPPβ), amyloid-β42 (Aβ42), and phosphorylated tau (P-tau181) were examined with respect to HOMA-IR and APOEɛ4 status. Delayed memory performance was examined with respect to HOMA-IR, CSF AD biomarkers, and APOEɛ4 status. RESULTS: Higher HOMA-IR was associated with higher sAβPPβ and Aβ42 . APOEɛ4 carriers had significantly higher levels of sAβPPα, sAβPPβ, and P-tau181/Aβ42 compared to noncarriers. The concurrent presence of higher HOMA-IR and CSF AD pathology predicted worse delayed memory performance. CONCLUSION: Overall, the findings suggest that IR and APOEɛ4 are contributing factors to the development of AD pathology in midlife, and provide support for targeting insulin function as a potentially modifiable risk factor for AD.
Entities:
Keywords:
APOEɛ4; CSF AD biomarkers; insulin resistance; memory function
Authors: Otto Tschritter; Hubert Preissl; Anita M Hennige; Michael Stumvoll; Katarina Porubska; Rebekka Frost; Hannah Marx; Benjamin Klösel; Werner Lutzenberger; Niels Birbaumer; Hans-Ulrich Häring; Andreas Fritsche Journal: Proc Natl Acad Sci U S A Date: 2006-07-28 Impact factor: 11.205
Authors: S Craft; S Asthana; G Schellenberg; L Baker; M Cherrier; A A Boyt; R N Martins; M Raskind; E Peskind; S Plymate Journal: Ann N Y Acad Sci Date: 2000-04 Impact factor: 5.691
Authors: Madhav Thambisetty; E Jeffrey Metter; An Yang; Hillary Dolan; Christopher Marano; Alan B Zonderman; Juan C Troncoso; Yun Zhou; Dean F Wong; Luigi Ferrucci; Josephine Egan; Susan M Resnick; Richard J O'Brien Journal: JAMA Neurol Date: 2013-09-01 Impact factor: 18.302
Authors: Auriel A Willette; Barbara B Bendlin; Erika J Starks; Alex C Birdsill; Sterling C Johnson; Bradley T Christian; Ozioma C Okonkwo; Asenath La Rue; Bruce P Hermann; Rebecca L Koscik; Erin M Jonaitis; Mark A Sager; Sanjay Asthana Journal: JAMA Neurol Date: 2015-09 Impact factor: 18.302
Authors: Calliope Holingue; Alexandra Wennberg; Slava Berger; Vsevolod Y Polotsky; Adam P Spira Journal: Metabolism Date: 2018-02-01 Impact factor: 8.694
Authors: Patrick J Smith; James A Blumenthal; Alan L Hinderliter; Stephanie M Mabe; Jeanne E Schwartz; Forgive Avorgbedor; Andrew Sherwood Journal: J Hypertens Date: 2019-05 Impact factor: 4.844
Authors: Jill K Morris; Roxanne Adeline Z Uy; Eric D Vidoni; Heather M Wilkins; Ashley E Archer; John P Thyfault; John M Miles; Jeffrey M Burns Journal: J Alzheimers Dis Date: 2017 Impact factor: 4.472
Authors: Stefan L C Geijselaers; Pauline Aalten; Inez H G B Ramakers; Peter Paul De Deyn; Annemieke C Heijboer; Huiberdina L Koek; Marcel G M OldeRikkert; Janne M Papma; Fransje E Reesink; Lieke L Smits; Coen D A Stehouwer; Charlotte E Teunissen; Frans R J Verhey; Wiesje M van der Flier; Geert Jan Biessels Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472